BioRestorative Therapies (BRTX) Research & Development (2011 - 2025)

BioRestorative Therapies (BRTX) has reported Research & Development for 15 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Research & Development rose 54.35% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $9.2 million (up 61.66% YoY), and the FY2025 full-year result was $10.1 million, up 50.51% from the prior year.
• Research & Development rose to $2.6 million in Q4 2025 per BRTX's latest filing, from $2.6 million in the prior quarter.
• Across five years, Research & Development topped out at $2.6 million in Q4 2025 and bottomed at $160898.0 in Q2 2021.
• Historically, Research & Development has averaged $1.2 million across 5 years, with a median of $1.1 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Research & Development slumped 38.48% in 2021, then surged 568.26% in 2022.
• Over 5 years, Research & Development stood at $165496.0 in 2021, then jumped by 307.03% to $673621.0 in 2022, then soared by 61.83% to $1.1 million in 2023, then jumped by 56.14% to $1.7 million in 2024, then jumped by 54.35% to $2.6 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $2.6 million, $2.6 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.